Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.

CORONARY disease; HEART disease risk factors; SCHIZOPHRENIA; COMORBIDITY; EPIDEMIOLOGY; METABOLIC disorders; DIAGNOSIS; DRUG therapy for schizophrenia; DIAGNOSIS of schizophrenia; METABOLIC syndrome diagnosis; ANTIPSYCHOTIC agents; COMPARATIVE studies; HIGH density lipoproteins; HYPERCHOLESTEREMIA; LIFE expectancy; LOW density lipoproteins; RESEARCH methodology; MEDICAL cooperation; CLASSIFICATION of mental disorders; RESEARCH; SMOKING; TRIGLYCERIDES; EVALUATION research; METABOLIC syndrome; DISEASE prevalence; SEVERITY of illness index

Objective: To determine the prevalence and characteristics of coronary heart disease (CHD) risk factors in patients with chronic schizophrenia or schizoaffective disorder.Method: We compared individual CHD risk factors and Framingham risk predictions in a group of 240 patients with a large national sample (Canadian Heart Health Survey) matched for age and sex. In addition, we compared rates of the metabolic syndrome (syndrome X) with recently published rates in the US adult population.Results: Compared with the reference population, Framingham 10-year risk of myocardial infarction was greater in the male patients (t3091 = 4.35, P < 0.001) but not in the female patients. Prevalence rates of the metabolic syndrome in the patients (42.6% of men and 48.5% of women) were approximately 2 times published rates in the US adult population. Further, the syndrome appears to occur at a younger age than in the general population.Conclusions: These long-term patients have increased CHD risks best captured by the metabolic syndrome conceptualization coupled with a high rate of cigarette smoking. This characterization is consistent with increased cardiovascular morbidity and decreased life expectancy in both men and women. We underscore the importance of both screening for and treating potentially reversible CHD risk factors in schizophrenia patients. [ABSTRACT FROM AUTHOR]

Copyright of Canadian Journal of Psychiatry is the property of Sage Publications Inc. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)